Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 447 participants.
Also called NCT01632163
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 447 participants
- Sponsor
- Registry
-
NCT01632163
-
- Other papers using this trial's data
- Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China, India, Russia, South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01632163. Randomized; triple masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2015-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Lixisenatide (AVE0010)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01632163- Content hash
6e305bf89e958d9f09e9d83bb65a4890ad79496355bce0fd6e6318f7cc578b7b